IDA in CKD is different, it’s complicated, and you have a blockbuster drug ($1 billion Renvela on steroids) with pristine clinical results for years. You also have 2 FDA approvals, the last one granted 5 months ago which exponentially increases market potential. You also have broad label EU approval since 21/2 years ago with New Active Substance designation which provides 10 years of data and marketing exclusivity in Europe.You also have 27,300 sq. ft. multi-million renovated offices with an organization structure a la Big Pharma footprint of 210 head count. You also have hefty compensation and benefit package with free stock awards/RSUs. You also just spent $100 million in SG&A in 2017.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.